| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4282424 | Annales de Chirurgie | 2006 | 6 Pages |
Abstract
These results (low mortality, significant distant survival including some long term survivors) suggest that PD for pancreatic adenocarcinoma must be indicated in most low-risk patients. PD remains the only curative treatment allowing prolonged survival.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
B. Morin, L. Chiche, E. Salame, G. Lebreton, V. Rouleau, P. Segol,